Blenrep 70mg/100mg powder for concentrate for solution for infusion
*Company:
GlaxoSmithKline (Ireland) LtdStatus:
UpdatedLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
File name
Belamaf Ireland - RMP Eye-related side effects guide for HCPs - Brochure - Feb 26.pdf
Reasons for updating
- Add New Doc
Free text change information supplied by the pharmaceutical company
First version of HCP guide
File name
Belamaf Ireland - RMP Eye-related side effects guide for patients - Brochure - Feb 2026.pdf
Reasons for updating
- Add New Doc
Free text change information supplied by the pharmaceutical company
First version of patient guide
File name
Belamaf Ireland - RMP Patient Wallet Card -Feb 2026.pdf
Reasons for updating
- Add New Doc
Free text change information supplied by the pharmaceutical company
First version of patient wallet card
Updated on 09 February 2026
File name
ie-spc-combined-blenrep-issue2draft1-clean .pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
change in section 5.1 is made: the dosing schedule for daratumumab in the DVd comparator arm for cycle =9
Renal impairment paragraph in section 5.2 Pharmacokinetic properties of the SmPC is being revised to incorporate updated pharmacokinetic data in patients with end-stage renal disease (ESRD) with or without dialysis.
Updated on 11 December 2025
File name
ie-spc-combined-blenrep-issue1draft1-meds.ie.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
New SPC for medicines.ie
Updated on 11 December 2025
File name
ie-pl-combined-blenrep-issue2draft1-meds.ie.pdf
Reasons for updating
- New PIL for new product
Free text change information supplied by the pharmaceutical company
New PIL for medicines.ie
GlaxoSmithKline (Ireland) Ltd
Address:
12 Riverwalk, Citywest Business Campus, Dublin 24, IrelandTelephone:
+353 1 495 5000Medical Information Direct Line:
1 800 244 255